1. Introduction
===============

HSV-1 is a widespread pathogen in the alphaherpesvirus family ([@veaa013-B55]). It is prevalent across the world, infecting an estimated 3.7 billion people, who experience a spectrum of disease outcomes from asymptomatic infections to recurring skin lesions or rarely, encephalitis ([@veaa013-B37]). HSV-1 productively replicates in epithelial cells and then latently infects neuronal cells, leading to lifelong persistence in the host. The virus can periodically reactivate from latency to productively replicate in epithelial cells, with the potential for multiple cycles of latency and reactivation from the neuronal reservoir over the life of an infected individual ([@veaa013-B55]). This replication strategy has great advantages for viral persistence, and it also provides multiple opportunities for the virus to evolve within a host. During each active replication event, the virus may undergo selection in response to the cellular and immunological selective pressures that it faces ([@veaa013-B25]; [@veaa013-B4]; [@veaa013-B16]; [@veaa013-B57]; [@veaa013-B38]). Following productive replication, the progeny viruses can either be transmitted to a new host or may re-enter the nervous system of the current host, potentially expanding the latent reservoir of virus for future reactivation cycles ([@veaa013-B31]; [@veaa013-B36]). As the selective pressures between epithelial and neuronal cellular environments are likely different, each cycle of latency and reactivation may create new genetic diversity in the viral population, which may be followed by a bottleneck upon the conversion to latency.

While cycles of latency and reactivation are a well-established and accepted aspect of herpesvirus biology ([@veaa013-B48]; [@veaa013-B55]), the concept of HSV-1 exhibiting substantial genetic diversity and evolutionary potential within an infected individual has only recently been established ([@veaa013-B4]; [@veaa013-B39]; [@veaa013-B46]; [@veaa013-B22]; [@veaa013-B49]; [@veaa013-B59]). As with other herpesviruses, HSV-1 has a large double-stranded DNA (dsDNA) genome, and these viruses have generally been considered to be genetically stable in comparison to viruses with an RNA genome ([@veaa013-B57]; [@veaa013-B56]). However, an increasing body of evidence supports the idea that herpesviruses, including HSV-1, exist as a diverse genetic population *in vivo* ([@veaa013-B13]; [@veaa013-B24]; [@veaa013-B51], [@veaa013-B52])*.* A similar level of diversity may exist *in vitro* as well, depending on the method of preparation (reviewed in [@veaa013-B49]). This genetic diversity can be generated through multiple mechanisms, including polymerase error, copy number variation, and recombination ([@veaa013-B25]; [@veaa013-B16]; [@veaa013-B35]). The HSV-1 polymerase has been previously demonstrated to have a low mutation rate (1 × 10^−7^ to 1 × 10^−8^ mutations per base per infectious cycle), although these studies were performed on a single gene in a unique coding region of the HSV-1 genome ([@veaa013-B25]; [@veaa013-B5]; [@veaa013-B16]). The HSV-1 genome consists of unique long (UL) and unique short (US) coding regions, which are flanked by large structural repeats \[Internal Repeat Long/Short (IRL/S), Terminal Repeat Long/Short (TRL/S)\]. Tandem repeats (TRs) occur frequently in the HSV-1 genome but are especially enriched in the IRL/S and TRL/S regions. Copy number variation or length fluctuations of tandem repeats and homopolymer tracts are a frequent source of genetic variation in strains of HSV-1 ([@veaa013-B62]). Repetitive regions of the HSV-1 genome also have very high G + C content, which favors recombination ([@veaa013-B35]). Recombination allows for increased genetic diversity in the absence of polymerase error, which may be especially relevant for herpesviruses ([@veaa013-B2]; [@veaa013-B35]; [@veaa013-B34]). These mechanisms contribute to a high level of variation in the large terminal and internal repeats, which contain genes that are critical to HSV-1 replication (ICP0, ICP4, y34.5) ([@veaa013-B63]; [@veaa013-B55]; [@veaa013-B47]). Crucially, HSV-1 is known to respond quite rapidly in response to strong selective pressures such as antiviral drug treatment, whether through *de novo* mutation or selection of existing variants in the population ([@veaa013-B25]; [@veaa013-B6]; [@veaa013-B58]; [@veaa013-B27].

The genetic diversity of a population of HSV-1 can undergo genetic drift (e.g., single nucleotide polymorphisms (SNPs), insertions/deletions (Indels), or TR length fluctuation) or even more dramatic genetic shifts (e.g., recombination) both *in vivo* and *in vitro*. There have been few studies that have followed a population of HSV-1 through longitudinal sampling of one person ([@veaa013-B59]), or studied known transmission events ([@veaa013-B46]). These studies imply that viral population diversity can be generally maintained through transmission ([@veaa013-B46]), but that the viral population can drift or adapt during subsequent rounds of latency and reactivation ([@veaa013-B59]). However, as with most viruses, HSV-1 is quite often studied in cell culture or animal models. Each of these approaches have limitations and differences from authentic replication in the natural host *in vivo*, with concomitant impacts on viral evolution and genetic diversity. As an example, HSV-1 is routinely propagated in monolayers of African green monkey kidney (Vero) cells. These cells support robust viral replication and are easily manipulated in a laboratory environment. However, these cells are not human in origin and they represent only one cell type (described as fibroblast-like) ([@veaa013-B65]) of the multiple epithelial and mucosal cell types that HSV-1 encounters in a normal human infection ([@veaa013-B55]). In addition to the lack of adaptive immune control in cell culture, Vero cells lack innate immune defenses, due to a defect in interferon signaling ([@veaa013-B18]; [@veaa013-B42]; [@veaa013-B65]). Finally, HSV-1 stocks are often passaged multiple times in Vero cells to amplify the virus, without considering the potential for genetic drift from the source stock. One classic approach used by virologists to reduce the potential for genetic drift was to isolate virus from individual plaques on a monolayer, which is referred to as plaque-purification. This practice constitutes a severe genetic bottleneck, which could lead to unexpected consequences if a rare or deleterious genetic variant is unintentionally selected ([@veaa013-B63]; [@veaa013-B28]; [@veaa013-B47]).

In this study, we utilized serial passage of two HSV-1 populations to begin to address several outstanding questions about the ability of this virus to evolve in cell culture. We utilized plaque morphology as an initial marker for genetic diversity, based on our prior observation that a frequently used HSV-1 strain (F) contained a mixture of syncytial and non-syncytial plaque phenotypes ([@veaa013-B63]; [@veaa013-B47]). We also used a 'purified' clonal population of the same strain of HSV-1, which was generated through plaque purification of a non-syncytial representative of strain F. By subjecting each of these viral populations to serial passage in Vero cells, we investigated the contribution of genetic diversity to viral fitness, detected the frequency and distribution within the genome of new genetic variants, and gained insight into the mechanisms underlying the generation and maintenance of genetic diversity. These results have ramifications for our understanding of the outcome of viral mutagenesis and generation of new recombinants *in vitro*, as well as shedding new light on the genetic diversity of HSV-1.

2. Materials and methods
========================

2.1 Cells and viruses
---------------------

Vero (African Green Monkey Kidney) cells (ATCC, CCL-81) were maintained at 37°C with 5 per cent CO~2~. Cells were cultured in Dulbecco's minimal essential medium (DMEM) supplemented with 10 per cent Fetal Bovine Serum (FBS), penicillin-streptomycin (Life Technologies---Gibco) and [l]{.smallcaps}-Glutamine (Thermo Fischer Scientific-HyClone). HSV-1 strain F has been previously described ([@veaa013-B63]; [@veaa013-B47]). In our previous description of mixed plaque morphologies in this stock of HSV-1 F, we referred to this stock as 'F~Original~', and here we refer to it as F-Mixed or Mixed throughout the paper. The Purified population used here is the same as the previously described F~Large~ ([@veaa013-B47]), which was obtained following three sequential plaque purifications. For [Fig. 7](#veaa013-F7){ref-type="fig"}, the purified Syncytial population (F-Syncytial) is the same as the previously described F~Syncytial~ ([@veaa013-B47])~.~ The consensus genome sequence of the Purified (F~Large~) population is GenBank accession [KM222724](KM222724) and that of the purified Syncytial population (F~Syncytial~) is GenBank accession [KM222725](KM222725). Clinical isolates shown in [Fig. 5](#veaa013-F5){ref-type="fig"} were collected at University of Washington from participants within one year of their first episode of genital HSV-1 infection. Isolates were collected from genital lesions, placed into viral transport media, and cultured once on Vero cells (Passage 0, P0) before transfer of samples to the Pennsylvania State University for further studies. The University of Washington Human Subjects Division reviewed and approved the collection of clinical isolates, and all participants provided written informed consent.

2.2 *In vitro* evolution experiments
------------------------------------

Each viral population was used to infect a T-150 flask of Vero cells at an MOI of 0.01 in DMEM with 2 per cent FBS, penicillin--streptomycin, and [l]{.smallcaps}-Glutamine. Seventy-two hours post-infection (hpi) virus was harvested by scraping, followed by three cycles of freezing and thawing. Each cycle of infection and harvest was considered a passage. The harvested virus was then titered on Vero cells using DMEM with 2 per cent FBS, penicillin--streptomycin, [l]{.smallcaps}-Glutamine, and methylcellulose. At 72 h post-infection, cell monolayers were fixed and stained with methanol and methylene blue. Following a determination of titer, plaque morphologies were identified by counting at least 200 plaques per passage. Plaques were counted as standard cytopathic effect (CPE) if they displayed rounding of individual cells after infection ([@veaa013-B47]). Plaques were counted as syncytial if they had a fused center, with the appearance of multiple nuclei within a shared membrane ([@veaa013-B47]). This process then continued through each of 10 passages to create a 'lineage'. For the Mixed population, three independent lineages were created.

2.3 Other viral infections
--------------------------

For the competition experiments in [Fig. 7](#veaa013-F7){ref-type="fig"}, Vero cells were infected at an MOI of 0.01, at the indicated ratios of F-Purified: F-Syncytial. For the growth curves in [Fig. 8](#veaa013-F8){ref-type="fig"}, Vero cell monolayers were infected at a MOI of 10 (single-step) or 0.01 (multiple-step) and harvested by scraping at the indicated time-points. Following three rounds of freezing and thawing, the resulting virus stock was titered on Vero cells as above. These experiments were performed in triplicate.

2.4 Next-generation sequencing
------------------------------

Next-generation sequencing was performed as previously described ([@veaa013-B47]). Briefly, nucleocapsid DNA was prepared by a high (MOI = 5) infection of Vero cells, followed by collection of cells and media. Nucleocapsids were isolated with Freon and pelleted through a glycerol gradient. Nucleocapsids were then lysed using SDS and Proteinase K, and viral DNA was extracted using phenol-chloroform. The viral nucleocapsid DNA was then used to prepare barcoded sequencing libraries, according to the Illumina TruSeq DNA Sample prep kit instructions. Libraries were quantified and assessed by Qubit (Invitrogen, CA), Bioanalyzer (Agilent), and library adapter qPCR (KAPA Biosystems). Illumina MiSeq paired-end sequencing (2 × 300 bp) was completed according to manufacturer's recommendations, using 17 pM library concentration as input to the MiSeq. A consensus viral genome for each strain was assembled using a *de novo* viral genome assembly (VirGA) workflow ([@veaa013-B47]). Consensus genomes for each population were aligned and visualized using Geneious ([@veaa013-B30]) (Biomatters). A multi-line fasta file of these consensus genomes, as well as the alignments used for [Fig. 2](#veaa013-F2){ref-type="fig"}, are available in a ScholarSphere data repository at this DOI: [https://doi.org/10.26207/t2vg-jd33](10.26207/t2vg-jd33).

2.5 Minor variant analysis
--------------------------

Minor variants (MVs) within each genome were detected using VarScan 2.4.2 ([@veaa013-B32]), in a similar manner as previously described ([@veaa013-B46]; [@veaa013-B3]; [@veaa013-B59]). We used parameters intended to eliminate sequencing-induced errors from the initial calling of MVs. Minimum variant allele frequencies ≥0.02; base call quality ≥20; read depth at the position ≥100; independent reads supporting minor allele ≥5. Minor variants with directional strand bias ≥90 per cent were excluded. MVs that passed these filters were then annotated onto the genome using SnpEff ([@veaa013-B9]) to determine their mutational effects. Finally, we used the alignment of the sequentially passaged consensus genomes to detect large gaps and/or insertions that were observed in single genomes, and to locally reassemble these suspected errors. Once curated, these genomes were re-analyzed for minor variants as before. See [Supplementary File 1](#sup1){ref-type="supplementary-material"} (Mixed viral populations) and [Supplementary File 2](#sup1){ref-type="supplementary-material"} (Purified viral populations) for full list of minor variants detected at each passage from P0 to P10. High confidence minor variants ([Fig. 5](#veaa013-F5){ref-type="fig"} and [Table 1](#veaa013-T1){ref-type="table"}) were defined by the presence of a given variant in 3 or more consecutive passages in a lineage for Lineage 1 or noted for presence at P10 for Lineages 2 and 3.

###### 

High confidence minor variants in F Mixed population (\* indicates variants highlighted in [Figure 5](#veaa013-F5){ref-type="fig"})

  Gene               Nucleotide Change           Variant Type     AA Change                  Allele frequency (Percent)                                                                                
  ------------------ --------------------------- ---------------- -------------------------- ---------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  UL7                C to T                      Synonymous       Phe209Phe                                                                    9.4    14.0   23.9   21.8   23.4   25.7   22.3          
  Between UL8/9      G to C                      Non-Coding                                  7.2                          6.4    8.1    5.9    9.2           10.6                                      
  Between UL8/9      G Deletion (Homopolymer)    Non-Coding                                                               14.3   13.4   12.9   17.0   13.8   6.5    12.8                 11.1          
  UL9\*              G to A                      Missense         Arg813His                  2.0                                 3.7    5.7    14.8   35.1   43.6   40.1                        10.1   10.9
  UL9\*              A to G                      Missense         His813Arg                                                                                                49.3   47.8   46.0          
  UL9                C to T                      Missense         Arg203Cys                                                             6.9    7.9    6.8    7.2           6.1    6.2    8.4    25.9   17.5
  UL9                G to A                      Missense         Arg200His                                                      2.2    3.6    3.6    7.2    6.0    6.4    8.4    8.7    9.2    22.3   13.0
  UL9                G to A                      Missense         Ser105Asn                                                             2.6           2.4    2.2    3.1    5.1    4.1    3.6           10.2
  UL9                A to G                      Missense         Ser105Gly                                                             2.3    3.8    5.6    5.4    8.0    10.3   12.5   15.0   14.4   14.7
  Between UL10/11    C Insertion (Homopolymer)   Non-Coding                                  4.3                          4.1    3.6    2.1    3.8    3.6    3.8    4.7    5.0    3.6    3.7    7.4    6.0
  UL12               C to T                      Synonymous       Leu287Leu                                                                    11.2   16.4   22.9   20.1   28.5   23.8   23.9          
  UL12               C to T                      Missense         Ala204Val                                                                           7.3    9.2    11.3   16.8   17.1   18.9          3.3
  UL13               C to T                      Missense         Arg432Cys                                               12.5   17.7   24.4   26.7   17.9   21.8   23.0   15.6   12.4   13.6   26.4   28.9
  UL13\*             G to A                      Premature Stop   Trp30Stop                  2.2                                               9.9    16.3   22.4   23.3   24.7   26.5   24.0          
  UL13\*             G Insertion (Homopolymer)   Premature Stop   Frameshift 118, Stop 161   45.0                                                                                                      
  UL13\*             G Deletion (Homopolymer)    Premature Stop   Frameshift 118, Stop 161                                47.5   35.0   27.8   19.0   10.3   10.0   6.2    6.0    3.3    2.3    4.7    3.2
  UL14               C to A                      Missense         Leu135Met                  2.5                          2.3    3.9    4.0    3.4    3.8    3.9    3.4           2.6    3.6    3.1    3.3
  UL14               C to T                      Synonymous       Asp132Asp                                               2.0    2.2    5.4    6.2    8.5    6.8    9.4    11.9   14.4   13.6   18.2   25.6
  UL14\*             G to A                      Missense         Val109Met                  13.5                         19.9   23.7   25.7   33.3   38.1   32.5   40.5   38.3   38.8   41.8   41.3   38.1
  UL14\*             G to A                      Missense         Val81Met                                                                     2.5    2.6    2.7    4.8    6.0    4.1                  
  UL16\*             C to T                      Missense         Leu261Phe                                                                           8.2    14.4   12.0   14.2   16.1   16.4          
  UL17               C to A                      Missense         Ala227Glu                                                                    2.1    2.0    3.4    3.7    4.3    4.2    2.7           
  UL17               G to A                      Missense         Ala3Thr                                                                      9.9    15.0   24.6   24.5   26.7   24.8   23.2          
  Between UL17/18    C Insertion (Homopolymer)   Non-Coding                                  3.1                                 5.8    5.0    5.4    4.5    6.9           4.9    4.7                  
  UL18               C to T                      Synonymous       Leu275Leu                                                                    2.4    3.3    3.1           2.5    3.1    3.4    10.6   12.0
  UL19               C to T                      Missense         Pro486Leu                                                                    2.5           2.5    3.0    3.7    3.0    3.5           4.2
  Between UL20/21    C to T                      Non-Coding                                                                             3.6    3.3    2.2    2.6    2.9    2.2    2.3           3.1    2.7
  Between UL22/23    C to G                      Non-Coding                                                                                    10.4   20.7   23.7   20.4   26.4   28.5   29.7          
  UL22               C to T                      Synonymous       Leu480Leu                                                             2.5    2.9    3.5    3.4    4.4    4.1    4.6    3.1    13.3   14.5
  UL24               C to T                      Missense         Arg63Cys                                                                            2.8    3.6    2.5    2.8    2.3    2.7           
  UL24\*             G to A                      Missense         Arg265Gln                                                                    8.1    12.8   18.9   18.8   25.1   22.9   22.4          
  UL25               G to A                      Synonymous       Pro146Pro                                                                           5.5    12.6   13.4   12.0   14.1   15.4          
  UL25               G to A                      Missense         Ala357Thr                                                                           3.0    2.9    4.3    3.5    2.7    2.1           
  Between UL25/26    T Insertion                 Non-Coding                                  16.0                         15.3   12.5   15.5   18.9   19.8   26.2   26.6   23.2   27.2   25.7   14.5   16.8
  UL26               G to A                      Synonymous       Ala263Ala                                                                           6.3    10.1   13.6   15.3   15.8   18.4   4.2    
  UL26               C to A                      Synonymous       Ala362Ala                                                                    3.2    2.7    3.5    4.0    3.8    4.4    2.8           
  Between UL26/27    T Insertion                 Non-Coding                                                                             4.8    3.4    3.4    4.2    3.5    5.8    4.4    5.5    19.5   7.1
  Between UL26/27    C to T                      Non-Coding                                                                             2.5    12.7   20.4   30.4   26.3   35.3   32.9   28.5   4.9    5.7
  UL27               G to A                      Missense         Arg885His                                                             2.9    3.5    4.1    5.4           4.8    4.3    5.2    8.5    4.7
  UL27\*             G to A                      Missense         Arg858His                                               3.5    5.8    12.4   26.2   31.0   46.3   49.0   48.6                        35.9
  UL27\*             A to G                      Missense         His858Arg                                                                                                       50.1   48.9   47.3   
  UL27\*             T to C                      Missense         Leu817Pro                                               2.8    6.9    14.7   17.2   21.1   32.8   36.1   40.1   41.0   46.3   30.9   47.6
  UL27               G to A                      Synonymous       Lys544Lys                                                                           7.9    10.5   13.4   17.7   15.9   16.0          
  UL30               C to T                      Missense         Ala25Val                                                                     2.8    3.3    2.9    2.9           2.5    4.6    13.5   14.5
  UL30               G to A                      Synonymous       Lys938Lys                                                                    8.6    15.3   20.8   20.2   20.7   21.8   23.6          
  UL30               G to A                      Missense         Arg181His                                                                           2.2    2.9    3.2    2.1    3.3    2.4           
  UL34               C to T                      Synonymous       Gly109Gly                                                                           6.1    8.8    10.5   12.7   14.9   13.4          
  UL36               G to A                      Missense         Ala981Thr                                                                           2.5    2.2    3.0    2.6    2.8           11.4   7.8
  UL36               C to T                      Missense         Thr860Met                                                                           3.2    2.6    3.4           2.3    2.5           
  UL37               C to T                      Missense         Ser890Leu                                                                           2.6    2.2           3.2    3.5    2.4           3.2
  UL39               G to A                      Synonymous       Gln736Gln                                                                                  3.1    3.2    3.7    2.8    2.8           
  UL40               C to T                      Synonymous       Leu301Leu                                                                           3.9    2.7    3.0    2.5    3.4    2.3    2.2    
  UL42               C to T                      Missense         Thr135Met                                                                           2.8    3.5    2.6    2.6                         
  UL42               C to T                      Synonymous       Leu325Leu                                                                    10.2   12.5   23.3   23.2   22.2   21.0   21.8          
  UL46               G to A                      Missense         Ala185Thr                                                                           2.0    2.4    3.7    2.1    2.2    2.9           
  Between UL49/50    G to A                      Non-Coding                                                                                                  2.1    3.2    2.6    2.2    2.7           
  Between UL53/54    G to A                      Non-Coding                                                                                                  2.9    3.4    3.6    3.6    3.2           
  UL52               G to A                      Synonymous       Gly2Gly                                                                      2.1           2.7    2.9    2.5                         
  Between UL56/IRL   C to T                      Non-Coding                                                                                    9.5    14.2   24.0   23.4          21.1   18.4          
  US6                G to A                      Synonymous       Gln52Gln                                                                                   2.0    2.0           3.3    3.0           
  US6                C to T                      Synonymous       Val356Val                                                                                  2.7    2.7    2.4                         
  US8A               A to G                      Missense         Thr109Ala                                                                    2.4    2.5    2.4    2.7                  2.1           
  US8A               C to T                      Missense         Ala149Val                                               2.6    2.4           2.9    2.5    2.2           2.3    3.1    2.6    3.8    5.0
  US9                G to A                      Missense         Val65Ile                                                                                          11.4   12.4   8.7    11.8          

indicates variants highlighted in [Figure 5](#veaa013-F5){ref-type="fig"}. See Supplementary Files 1 (Mixed) and 2 (Purified) for full lists of Minor Variants in all passages of Lineage 1.

Minor variants also detected via deep-sequencing of Passage 10 (P10) of Lineages 2 or 3 (L2/L3) are listed as well.

2.6 Data availability
---------------------

Consensus genomes for starting viral populations have been deposited in GenBank as follows: Purified (F~Large~), [KM222724](KM222724); purified Syncytial (F~Syncytial~), [KM222725](KM222725); Mixed (F~Original~), GU734771. The alignments used for [Fig. 2](#veaa013-F2){ref-type="fig"}, which include the consensus genomes of all of the passaged viral populations, have been deposited at ScholarSphere: [https://doi.org/10.26207/t2vg-jd33](10.26207/t2vg-jd33). Raw sequence reads are available at the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) as Bioproject ID PRJNA565399.

Results
=======

3.1 Viral phenotypes can evolve over sequential passage in culture
------------------------------------------------------------------

While viruses with a DNA genome are often considered genetically stable ([@veaa013-B57]; [@veaa013-B56]), they are able to evolve rapidly in response to strong selective pressures, such as antiviral drug selection ([@veaa013-B6]; [@veaa013-B58]; [@veaa013-B27]). It is becoming increasingly evident that these viruses, including HSV-1, can exist as populations that contain significant genetic diversity ([@veaa013-B51]; [@veaa013-B49]). We sought to determine the effects of this genetic diversity on the *in vitro* evolution of HSV-1, in the context of the selective pressures present in Vero cell culture. To conduct these experiments, we used two related starting populations of HSV-1 strain F. The F-Mixed population (subsequently 'Mixed') is representative of the original HSV-1 F strain that was previously described to contain ∼3 per cent syncytial plaques, as well as an unexpected UL13 frameshift mutation ([Fig. 1](#veaa013-F1){ref-type="fig"}) ([@veaa013-B63]; [@veaa013-B47]). This variability in plaque phenotype was an early indication that the Mixed population was genetically heterogeneous. The F-Purified population (subsequently 'Purified') was derived from the Mixed population by three rounds of sequential plaque purification of a non-syncytial variant ([@veaa013-B63]; [@veaa013-B47]). It displays a homogenous, non-syncytial plaque morphology ([Fig. 1](#veaa013-F1){ref-type="fig"}). Each viral population was used to infect a separate monolayer of Vero cells at a MOI of 0.01. Following lysis of the cell monolayer, the resulting sample was harvested, titered, and examined for plaque morphology. This procedure is referred to as a passage for the purposes of these experiments. The titered viral stock from the first passage was used to infect the next monolayer of Vero cells at the same low MOI, and this process was repeated for 10 sequential passages. The viral population at each passage was also deep-sequenced ([Fig. 1](#veaa013-F1){ref-type="fig"}). Low MOI conditions were chosen to allow for multiple rounds of replication in each passage, enabling the most fit viral genotypes to expand in the population.

![Schematic of the *in vitro* evolution experiment approach and observed changes in plaque morphology: two populations of HSV-1 strain F were used to infect Vero cells at a multiplicity of infection (MOI) of 0.01. After infection was allowed to proceed for 72 h, progeny viral populations were harvested. This infectious cycle is referred to as a passage, and each viral population was carried through ten passages. Following each passage, each viral population was titered, visually examined for plaque morphology (see 'Materials and Methods' section for details), and prepared for sequencing. The entire series of 10 passages was performed in triplicate for the Mixed population and once for the Purified population. All replicates were titered and quantified for plaque morphology. Deep sequencing was performed on one lineage for each starting viral population. Plaque images were obtained by plating virus at limiting dilution on monolayers of Vero cells, then fixing and staining with methylene blue at 72 hpi. Tiled images (6 × 6) were exported from Nikon NIS-Elements software, and contrast inverted using Adobe Photoshop to show plaques more clearly. Scale bars indicate 2 mm.](veaa013f1){#veaa013-F1}

Over the course of ten sequential passages, we noticed dramatic changes in plaque morphology in the Mixed population ([Figs 1](#veaa013-F1){ref-type="fig"} and 2A). However, we did not observe substantial changes in viral titer across the ten passages in either viral population ([Fig. 2B](#veaa013-F2){ref-type="fig"}). At passage 0 (P0), we observed ∼3 per cent syncytial plaques in the Mixed population. The frequency of syncytial plaque-forming viruses in the population increased steadily with each passage, until nearly 100 per cent syncytial plaques were observed at passage 10 (P10). The conversion from predominantly non-syncytial to syncytial plaques in the population was observed in three independent lineages of the passaging experiment ([Fig. 2A](#veaa013-F2){ref-type="fig"}). In contrast, the Purified population did not contain any syncytial plaques at P0, and the syncytial plaque phenotype was not acquired over the course of ten passages. Using plaque morphology as a visual marker of genetic diversity, these results suggested that the more genetically diverse Mixed population was better able to adapt or evolve over the course of this experiment.

![Gross changes in plaque morphology occur over sequential passages, while consensus-level genome changes are limited. (**A**) Plaque morphology was quantified for each passage of the Mixed and Purified viral populations. The Mixed population was passaged for three independent lineages (A, B, and C). (**B**) The viral titer was measured at each passage of the Mixed and Purified lineages. (**C**) A diagram of the full-length HSV-1 genome, depicts the structural repeats and major sites of tandem repeats (black boxes). An alignment of the consensus genome for each of ten passages of the Mixed and Purified viral populations are shown here. Each genome is represented by a gray bar and passages are displayed in order (P0--P10). Identical sequences are noted by gray in the identity plot above the alignment, with yellow and red indicating lesser levels of identity across the alignment. The terminal repeats (TRL/TRS) are trimmed from the consensus genomes as to not over-represent diversity in these duplicated regions. (UL, Unique Long; US, Unique Short; TRL, Terminal Repeat Long; IRL, Internal Repeat Long; IRS, Internal Repeat Short; TRS---Terminal Repeat Short, a/a', repeat-containing site involved in genome cleavage and packaging).](veaa013f2){#veaa013-F2}

3.2 Few changes in consensus genomes were observed over ten passages
--------------------------------------------------------------------

Because each independent Mixed lineage displayed similar changes in plaque morphology, we chose one lineage each for Mixed and Purified viral populations and used high-throughput sequencing (HTS) to examine the viral genetic diversity at each passage. Full-length, consensus genomes were assembled for each passage using a *de novo* assembly pipeline ([@veaa013-B47]). We describe these as consensus genomes because they condense the sequencing results from the entire viral population into the most common nucleotide observed at each location in the genome ([@veaa013-B49]). Therefore, these genomes represent the consensus of the sequencing reads that were aligned to each position. We found that the consensus genomes were similar overall from passage to passage within the same lineage (i.e. Mixed versus Purified), which enabled curation and improvement of the assembled sequences. The high percent identity of a full-genome alignment derived from each set of ten passages is presented in [Fig. 2C](#veaa013-F2){ref-type="fig"}. While the consensus genomes were generally similar, sequence variation was observed in highly repetitive regions of these consensus genomes, where assembly of the HSV genome from short-read sequencing is technically challenging ([@veaa013-B49]). These regions include the PQ amino acid repeats in the gene encoding the tegument protein VP1/2 (UL36), the inverted repeats surrounding the lytic origin of replication (OriLyt), and the large internal and terminal copies of the repeats flanking UL and US (IRL/S and TRL/S) ([@veaa013-B63]). Surprisingly, the Mixed viral population did not display differences in genes associated with syncytia formation in the consensus genomes until passage 8 (P8). This genetic data differs from the timing of our visual detection of the syncytial plaque phenotype, which represented a majority of the observed plaques by P4. The asynchrony of consensus-level genomic data with the visually observable phenotype motivated a deeper analysis of the sequencing results, to analyze how minor alleles in the viral population may be contributing to the observed diversity in phenotypes.

3.3 Minor variants reveal evolution in the viral population
-----------------------------------------------------------

Because the analysis of consensus genomes from the passaged viral populations was insufficient to explain the observed phenotypic differences, we analyzed the sequencing data for evidence of genotypes that were detected as minor alleles in the viral population. These minor variants, which we define as nucleotide alleles present in \<50 per cent of the sequencing reads at a given locus, are not otherwise represented in the consensus genomes. With sufficiently deep sequencing coverage, these variants can generally be identified with confidence. The assembled genomes across all ten passages had an average coverage depth of 563 reads/position for the Mixed viral population and 517 reads/position for the Purified viral population. We identified nucleotide substitutions and insertions/deletions (indels) that were present in greater than 2 per cent but \<50 per cent of the sequencing reads for a given sample (2 per cent cutoff as the threshold of detection; see 'Materials and methods' for additional criteria.) Since the frequency of sequencing reads is correlated with the frequency of alleles in the population, this analysis revealed the genetic diversity present in each starting population, as well as the specific changes that occurred over passage, and their relative proportion in each sequential passage.

For each minor variant, we examined its position in the genome as well as its frequency in the population. We detected minor variants in each viral population, albeit at different sites and frequencies in each passage and population ([Figs 3 and 4](#veaa013-F3){ref-type="fig"}; see Supplementary Files 1 and 2 for full list). Both viral populations had minor variants in highly repetitive areas of the genome, but the Mixed viral population also had multiple minor variants in the unique (e.g., UL) coding regions ([Figs 3A and 4A](#veaa013-F3){ref-type="fig"}). As each virus population was passaged, the pattern of observed minor variants became more distinct. The Mixed population became more diverse, with new minor variants detected throughout the genome, and in a substantial percentage of the overall virus population ([Fig. 4A](#veaa013-F4){ref-type="fig"}). In contrast, the vast majority of detected minor variants in the Purified population were in the highly repetitive regions of the HSV-1 genome ([@veaa013-B49]) ([Figs 3B and 4B](#veaa013-F3){ref-type="fig"}). These results indicated that the initially higher level of genetic diversity in the Mixed population (i.e., Mixed P0 in [Fig. 3A](#veaa013-F3){ref-type="fig"} versus Purified P0 in [Fig. 3B](#veaa013-F3){ref-type="fig"}) likely seeded the future evolution of that viral population.

![Minor variants are widespread in the mixed, but not the purified, viral populations. Each passage of the (**A**) Mixed and (**B**) Purified viral populations were sequenced and analyzed for minor variants. A subset of passages are shown here for space considerations. Each minor variant present in 2% or more of the viral popiulation is shown as a vertical bar, and multiple variants within one gene are connected with a horizontal line. A plot of sequence read depth across the HSV-1 genome is shown for P0 of each virus population (results are representative of all passages). Across all passages, the average coverage depth across the genome was 563 reads/position for the Mixed viral populations and 517 reads/position for the Purified viral populations. A diagram of the HSV-1 genome is shown in each panel for spatial orientation.](veaa013f3){#veaa013-F3}

![Minor variants in the mixed viral populations occur at more diverse locations and at higher frequencies than in the purified viral populations. Minor variants were plotted according to their location in the genome (*x*-axis), as well as by their observed frequency in each passage of these viral populations (*y*-axis). Variants that occurred in the same genomic location are seen as vertical columns of dots. Lighter colors indicate variants observed in earlier passages, whereas darker colors indicate later passages. Overall, a larger number and higher frequency of minor variants are observed in (**A**) the Mixed viral population than in (**B**) the Purified viral population. Highly repetitive regions of the HSV-1 genome are denoted by black bars (OriLyt, UL36 PQ repeats, and the internal repeat region) and gray vertical columns.](veaa013f4){#veaa013-F4}

While the repetitive regions of herpesvirus genomes have previously been demonstrated to be areas of high variability ([@veaa013-B63], [@veaa013-B62]; [@veaa013-B35]; [@veaa013-B47]), it is difficult to measure length fluctuations and other variations using short-read HTS technology in these regions ([@veaa013-B49]). To surmount this challenge, we used the sequential nature of these passages to identify minor variants with high confidence, due to their appearance in multiple sequential passages. We identified a number of these high-confidence minor variants ([Table 1](#veaa013-T1){ref-type="table"}) in the Mixed population lineage. In contrast, we were unable to identify any such high-confidence variants of this type in the Purified population lineage. While we cannot disregard the minor variants that sporadically appear in both of these viral populations, the lack of observed consistency from passage to passage makes these sporadic minor variants more difficult to conclusively identify, especially when they occurred in the aforementioned repetitive regions. This suggests that if these variants do arise, they are not increasing in frequency (e.g., due to positive selection), or that the low number of virions transferred at each passage is not allowing them to continue in the time course (i.e., an MOI = 0.01 uses \<0.01 per cent of the \>10^9^ PFU in each stock). These data suggest that when HSV-1 has a more diverse starting genetic population (i.e., the Mixed population), it is more able to change in response to the pressures of a given environment.

3.4 Frequency of minor variants may reveal selective pressures *in vitro*
-------------------------------------------------------------------------

We next investigated the types of minor variants that were present and how their frequencies changed over sequential passages of the viral population. We found that most of the high-confidence minor variants were missense mutations, though examples of non-coding and synonymous or silent mutations were also identified ([Table 1](#veaa013-T1){ref-type="table"}). Many minor variants increased as a percentage of the population over sequential passage, while others seemed to reach an equilibrium level of standing variation ([Fig. 5A](#veaa013-F5){ref-type="fig"} and [Table 1](#veaa013-T1){ref-type="table"}). We did not observe any minor variants that were clearly linked as a haplotype, in that their frequencies did not change in parallel. Accordingly, we treated each minor variant an individual contributor to the population. Minor variants that significantly increased in the viral population potentially conferred a selective advantage under these experimental conditions. This outcome is most clearly illustrated by the syncytia-inducing variants in UL27 (glycoprotein B, gB), which match previously described spontaneous mutations observed in this and other strains of HSV-1 ([@veaa013-B7]; [@veaa013-B19]; [@veaa013-B15]; [@veaa013-B54]).

![Minor variant dynamics shift over sequential passages *in vitro*. (**A**) A subset of the observed high-confidence minor variants in the Mixed population were plotted by their frequency in the viral population over passage (see [Table 1](#veaa013-T1){ref-type="table"} for full list of minor variants). Each variant would cause a change in the translated protein, whether through premature stop (UL13 S118\[F.S.\], W30\*stop) or a missense variant (all others). Variants and their encoded proteins are listed in the legend according to their frequency at passage 10 (P10). (**B**) A diagram of the UL13 protein (518 AA in length) depicts the location of the six previously described catalytic domains of this kinase ([@veaa013-B60]), with an asterisk (\*) denoting the catalytic lysine where a single point mutation can disrupt kinase activity ([@veaa013-B8]; [@veaa013-B29]). The minor variants observed in this study, and consensus-level mutations observed in other virus strains in prior studies, are indicated by arrows and labels. GenBank accessions: strain F, [GU734771](GU734771) ([@veaa013-B63]); E25, HM585506; E06, HM585496; E11, HM585500 \[all three from ([@veaa013-B62])\]; OD4, JN420342 ([@veaa013-B35]). (**C**) The minor variants observed in the UL13 gene were separated for specific analysis. Each variant is predicted to produce a catalytically-inactive UL13 kinase. Additive Effect refers to the arithmetic addition of the frequency of each of these two individual variants. (**D**) New clinical isolates of HSV-1 were passaged in Vero cells, genome sequenced, and examined for minor variants in the UL13 gene at each passage. The frequency of genetic variants that would produce an inactive UL13 kinase are plotted over each passage.](veaa013f5){#veaa013-F5}

Other minor variants appeared to reach an equilibrium in frequency within the viral population, which is a more difficult pattern to interpret. We found a particularly intriguing example of equilibration within the population with minor variants present in the UL13 gene. UL13 is the HSV-1 encoded representative of the Conserved Herpesvirus-encoded Protein Kinases (CHPK). UL13 kinase activity is dispensable *in vitro* ([@veaa013-B21]), but it is required for axonal transport *in vivo* ([@veaa013-B10]). The kinase domain of this enzyme is located in the C-terminal end of the protein, with the crucial catalytic lysine located at amino acid 176 ([Fig. 5B](#veaa013-F5){ref-type="fig"}) ([@veaa013-B29]; [@veaa013-B8]; [@veaa013-B20]). We identified two distinct minor variants that would cause premature termination of UL13 and would not be anticipated to have any kinase activity. We refer to these variants as W30\*stop, a missense mutation, and Frameshift Stop (or S118\[F.S.\]), an indel in a homopolymer ([Fig. 5B and 5C](#veaa013-F5){ref-type="fig"}). The Frameshift Stop insertion was present in a slight majority of the initial population (51 per cent) and it rapidly declined in frequency over sequential passages. However, the W30\*stop variant increased in frequency in the population over the same passages. In combination, these two presumably defective variants of the UL13 gene added up to a stable level of ∼30 per cent of the viral population. Thus, we observed a tolerance and/or a selection of UL13 variants that would presumably produce inactive kinases ([Fig. 5B and 5C](#veaa013-F5){ref-type="fig"}).

The presence of defective UL13 variants in HSV-1 populations is not unique to the F strain. In a recent publication by our group that compared a cultured clinical isolate to direct-from-patient swab-based sequencing of a genital HSV-1 lesion, we detected UL13 minor variants only in the cultured material ([@veaa013-B59]). We extended this investigation to two newly isolated clinical genital HSV-1 isolates, and likewise detected UL13-inactivating minor variants in these cultured populations. These variants rose in frequency over the initial passages *in vitro*, reaching substantially higher levels, in fewer passages, than the rate of change observed in the Mixed population ([Fig. 5D](#veaa013-F5){ref-type="fig"}). It is as yet unknown why these viral populations would maintain standing variation in the UL13 gene, and/or favor the inactivation of UL13 in Vero cell culture.

3.5 Syncytial phenotype is favored in Vero cells
------------------------------------------------

While the role of UL13 in Vero cell culture remains unclear, it is clear that the syncytial plaque phenotype is favored under these conditions. Three independent lineages of Mixed viral populations became dominated by syncytial variants ([Fig. 2](#veaa013-F2){ref-type="fig"}) under these experimental conditions, and the selective advantage of syncytia formation in Vero cell culture has been previously reported ([@veaa013-B44]). However, it is known that a syncytial phenotype can be caused by multiple independent genetic variants, and we can infer that each syncytial variant could have a different effect on viral fitness. We were able to identify two previously described syncytial variants in the Mixed viral population, both of which affect the gene encoding gB (UL27), at amino acids 817 (L to P) and 858 (R to H) ([@veaa013-B7]; [@veaa013-B19]; [@veaa013-B15]; [@veaa013-B54]) ([Fig. 6](#veaa013-F6){ref-type="fig"}). Each of these variants steadily increased in frequency within the viral population over subsequent passages, but neither variant reached a majority of the population (and therefore became represented in the consensus genomes) until P8 ([Fig. 6C](#veaa013-F6){ref-type="fig"}). As noted above, even when the visually observed phenotype indicated that the viral population was 88 per cent syncytial (P7, [Fig. 2A](#veaa013-F2){ref-type="fig"}), there was no genetic evidence of this at the level of the consensus genome. Intriguingly, while neither variant alone was sufficient to account for the entirety of this widespread syncytial phenotype, simply adding the frequency of each variant in the population neatly mirrored the frequency of syncytial plaques ([Figs 6C and 2A](#veaa013-F2){ref-type="fig"}).

![The combination of individual variants in gB (UL27) explained the syncytial phenotype observed in the Mixed viral population. The UL27 gene encoding gB includes two syncytia-inducing minor variants that encode an Arginine to Histidine change at amino acid 858 or a Leucine to Proline change at amino acid 817. Sequencing reads that span the nucleotides encoding both sites were identified for each passage. (**A**) Shown here is a random subset of the passage 7 (P7) sequencing reads surrounding this region, of which a total of 366 reads span both minor variants. The consensus genome is displayed at the top, with individual sequencing reads aligned below (yellow indicates forward-aligning sequencing reads, while purple indicates the reverse). Nucleotides matching the consensus genome are not shown, such that minor alleles that do not match the consensus sequence are the only ones highlighted. The relevant stretches of these sequencing reads are magnified, with any nucleotide that varies from the consensus genome noted (C--T for Arg858His or A--G for Leu817Pro). Note that the UL27 gene is on the reverse strand of the HSV-1 genome, so that the depicted nucleotides are in the reverse complement of what would be transcribed to produce the UL27 mRNA. (**B**) Across all ten passages, the percent of sequencing reads spanning this region that contained one, both, or neither variant is summarized here. Data for 'both' are included but are not visible on the graph, since only six sequence reads ever included both variants (three at P5, and three at P9). The yellow background panel in (B) connects the subset of P7 sequence read data shown in (**A**) to the relevant overall P7 percentage data graphed in (**B**). (**C**) The frequency of each variant in gB (UL27) was plotted alone, or as the sum of their frequency (Additive Variation (Var.)).](veaa013f6){#veaa013-F6}

These data suggest that each of these syncytial variants in gB occurred and proliferated independently. Therefore, we sought to address whether or not these variants ever co-occurred on the same stretch of DNA. The proximity of these variants in the genome enabled us to identify a number of sequencing reads, each corresponding to one physical piece of DNA, that spanned both minor variant loci in gB (UL27) ([Fig. 6A](#veaa013-F6){ref-type="fig"}). We detected each minor variant within this subset of reads at a frequency that was comparable to the overall frequency of the variant in the population ([Fig. 6B--6C](#veaa013-F6){ref-type="fig"}). We found that each variant occurred independently. Across all reads spanning these loci in ten passages, we found only six instances of these minor variants co-occurring in a single sequence read. We interpret these results as an indication that the syncytial phenotype, rather than any individual genetic variant, is being selected for under these conditions of Vero cell culture.

To test this hypothesis, we conducted a competition experiment in which two purified populations of HSV-1 were mixed in defined ratios and allowed to replicate under the same conditions as the original *in vitro* evolution experiment. We made use of a previously described syncytial clone of the F-Mixed population ([@veaa013-B63]), which carries the R858H syncytial variant in gB, as well as the same F-Purified population as was used in [Fig. 1](#veaa013-F1){ref-type="fig"}. These purified populations of uniformly syncytial or uniformly non-syncytial viruses were competed in defined ratios, where one or the other plaque phenotype was dominant at the start (50:1, 5:1, 1:5, and 1:50, Syncytial: Non-Syncytial). We also included one case of equal starting input (1:1, Syncytial: Non-Syncytial). As in the original *in vitro* evolution experiment, we found that the viral populations eventually displayed a syncytial plaque phenotype ([Fig. 7A](#veaa013-F7){ref-type="fig"}). The starting ratio influenced the rate of syncytial virus takeover, as shown by the slopes of each curve in [Fig. 7](#veaa013-F7){ref-type="fig"}. However, all ratio mixtures were predominantly syncytial by P10. Sanger sequencing of the gB (UL27) tail region (containing residues 817 and 858) in the tenth passage of the 1:5 and 1:50 mixes ([Fig. 7B](#veaa013-F7){ref-type="fig"}) suggests that the initial F-Syn population expanded to dominate in the mixed populations, rather than the syncytial phenotype occurring due to *de novo* mutations over passage. These results are similar to those obtained in the initial *in vitro* evolution experiment, where the R858H and L817P variants in gB were observed at very low levels in the initial Mixed population (R858H, 1.1 per cent; L817P, 1.4 per cent---below our threshold for reporting minor variants), before expanding over passage. Combined with the results observed in the Purified population passages, the data imply that in these experimental conditions we predominantly observed an expansion of more fit genotypes in the population, as opposed to *de novo* genetic variation.

![Defined mixtures of purified syncytial and non-syncytial HSV-1 populations reveal a universal advantage of the syncytial phenotype during sequential passage in Vero cells. (**A**) Purified populations of HSV-1 that displayed a uniformly syncytial or non-syncytial phenotype were mixed in defined ratios (as shown in legend) and allowed to compete during sequential passages of infection on Vero cells. At each passage, the plaque morphology of the resulting viral population was counted and plotted as the percentage of total plaques that were syncytial. MOI (0.01) and time to harvest (72 hpi) of each passage are the same as the initial *in vitro* evolution experiment described in [Figure 1](#veaa013-F1){ref-type="fig"}. (**B**) The tail region of gB (encoded by UL27) that contains the L817P and R858H variants described in [Figure 6](#veaa013-F6){ref-type="fig"} was Sanger sequenced from each purified starting population, the Mixed P10 population, and the 1:5 and 1:50 passage 10 (P10) populations. Representative traces are shown with the key nucleic acids highlighted, for the non-syncytial stocks (e.g., Purified), for the mixed population (e.g., Mixed), and for the syncytial stocks (shown here is 1:50 P10; similar data for purified syncytial and 1:5 P10 are not shown). Note that these reads are the reverse-complement of those shown in [Figure 6](#veaa013-F6){ref-type="fig"}.](veaa013f7){#veaa013-F7}

3.6 Genetic variation outside of syncytia formation facilitates viral fitness
-----------------------------------------------------------------------------

Finally, we examined whether or not each evolved viral population was more fit for replication than the starting population. To do this, we compared the single-step and multiple-step growth kinetics for representative populations of the passaged viruses. We chose P0, P5, and P10 as representative of the Mixed viral population at the starting, midpoint, and endpoint of the *in vitro* evolution experiment. For the Purified viral population, we examined only the P0 and P10 populations, due to the limited genetic changes observed in that viral population. Under both single-step growth conditions (MOI = 10), and multiple-step growth conditions (MOI = 0.01), we found that the passaged viral populations increased in titer to a greater degree than their original starting populations ([Fig. 8](#veaa013-F8){ref-type="fig"}). The differences in replication between passaged and input viral populations were statistically significant (*P* \< 0.05) at the final two time points in both growth curves (Two-way ANOVA), although the final titers of these stocks were overall quite similar ([Fig. 8](#veaa013-F8){ref-type="fig"} and [Fig. 2B](#veaa013-F2){ref-type="fig"}). Despite the continued genetic changes between P5 and P10 for the Mixed viral population, we did not detect any additional increases in replication by P10 in these assays. It is possible that the effect of these genetic changes is more subtle than can be detected by the assays and/or time-points chosen in these experiments.

![Passaged virus populations replicate more than input viral populations. Viral populations from the indicated passages of the Mixed or Purified stocks were used to infect Vero cells in (**A**) a single step growth curve (MOI = 10), or in (**B**) a multiple step growth curve (MOI = 0.01). Each assay was done in triplicate, with viral harvest and quantification by titering at the indicated timepoints. Data are plotted as titer compared to the first time-point for each experiment (2 h for A, 12 h for B). Error bars indicate standard deviation. In both growth curves, comparisons of passaged viral populations versus the input viral populations were significantly different at the final two time-points (two-way ANOVA, *P* \< 0.05).](veaa013f8){#veaa013-F8}

4. Discussion
=============

In this study, we examined the evolution of HSV-1 during viral replication *in vitro*. We sequentially passaged either a mixed or a purified population of HSV-1 in Vero cell culture, and we quantified the outcome both in terms of observed phenotypes and in genomic changes over time. These approaches enabled us to monitor how the viral population changed from passage to passage, to detect potentially advantageous viral genotypes and/or phenotypes under these conditions, and to examine how a diverse versus a homogeneous pool of viral genomes impacted the subsequent genetic drift of each viral population. We found that the more diverse ('Mixed') viral population was much more prone to change during passaging, with a syncytial plaque phenotype emerging as an advantageous trait under these Vero cell culture conditions. While the selection for syncytial plaques in Vero cell culture has been observed previously ([@veaa013-B44]), the precise mechanisms for this selection remain unclear. It is possible that syncytia allow the virus to spread to uninfected cells more rapidly than the non-syncytial phenotype and expand in the viral population ([@veaa013-B67]).

In addition to the genetic variants associated with syncytia formation, we observed the proliferation of a multitude of other genetic variants that may also confer a selective advantage in Vero cell culture conditions. Because Vero cell culture is the main methodology behind HSV-1 and HSV-2 propagation in most virology labs, both in experimental and diagnostic lab settings, these data provide key insights on the need to detect and understand viral evolution and selection *in vitro*. This is especially critical if the goal is to use laboratory observations to improve our understanding of viral population dynamics in actual human infections.

From these experiments, we were able to gain a number of useful insights for HSV-1, which may well extend to other herpesviruses and large DNA viruses. First, these experiments emphasized the contributions of standing variation and genetic diversity to HSV-1 evolution. While few would suggest that viruses with a large dsDNA genome do not evolve, the prevailing sentiment is that DNA viruses have a substantially slower rate of evolution than RNA viruses ([@veaa013-B57]; [@veaa013-B50]). Thus, the concept of quasispecies or of viruses existing as populations with a mixture of genotypes has generally been limited to the RNA virus world. However, recent experiments that take advantage of modern deep-sequencing technology have shown that dsDNA viruses possess substantial genetic diversity *in vivo* as well as in laboratory conditions ([@veaa013-B61]; [@veaa013-B12]; [@veaa013-B14]; [@veaa013-B17]; [@veaa013-B52]; [@veaa013-B47]; [@veaa013-B45]; [@veaa013-B43]; [@veaa013-B53]; [@veaa013-B46]; [@veaa013-B66]; [@veaa013-B64]). The diversity of genomes in an RNA virus population has been linked to viral fitness ([@veaa013-B1]; [@veaa013-B33]), and there is no reason to expect a different result with DNA virus populations. Indeed, in these experiments, the genetically diverse ('Mixed') viral population was able to adapt more readily to replication in Vero cells, while the more homogeneous ('Purified') population appeared to be much more stable.

From a technical standpoint, these experiments highlighted the usefulness of deep sequencing for the analysis of viral populations. If we were to assume that the consensus genomes of each Mixed passage were indicative of the entire viral population, we could not have explained why there were more syncytial plaques observed over sequential passages, because the consensus genome did not change until passage 8 (P8). A focus solely on consensus-level genome analysis would also have missed the dynamics of the inactivating variants of UL13, not to mention the array of other genetic variants that fluctuated in the Mixed viral population ([Fig. 5A](#veaa013-F5){ref-type="fig"}, [Table 1](#veaa013-T1){ref-type="table"}). Limiting the genetic analysis to the consensus level, particularly when using deep-sequencing approaches, eliminates a great deal of useful information about the viral population ([@veaa013-B49]). When performing similar evolution experiments to those performed here, but with different viruses, other researchers have found the most compelling evidence of evolution at the minority variant level ([@veaa013-B17]; [@veaa013-B26]; [@veaa013-B23]; [@veaa013-B40]; [@veaa013-B41]).

Several of the specific minor variants observed in this study are ones that have been previously noted to occur spontaneously in HSV-1 and related herpesvirus strains during propagation *in vitro*. For instance, the occurrence of spontaneous syncytia-inducing mutations in the gene encoding gB (UL27) has been well-documented in the literature ([@veaa013-B7]; [@veaa013-B19]; [@veaa013-B15]; [@veaa013-B54]). Likewise, the appearance of mutations that truncate the UL13 kinase, whether through an early stop codon or a frameshift, have been previously noted in multiple strain of HSV-1 by our lab and others ([@veaa013-B63], [@veaa013-B62]; [@veaa013-B35]) ([Fig. 5B](#veaa013-F5){ref-type="fig"}). Despite prior observation in the literature, earlier works have not connected these variants to a fitness advantage in Vero cell culture per se. For instance, early studies noting the selective advantage of HSV-1 syncytial phenotypes in cell culture did not have knowledge of the genetic basis of these phenotypes, and thus could not track these genetic variants over time ([@veaa013-B67]; [@veaa013-B44]). Future work is now warranted to investigate the potential positive selection of these and the other minor variants detected here that rise in frequency over sequential passages (e.g., [Fig. 5A](#veaa013-F5){ref-type="fig"}). The rapid rise in frequency of UL13 variants observed in early passages of two clinical isolates ([Fig. 5D](#veaa013-F5){ref-type="fig"}) suggests that the initial passages of new clinical isolates may serve as a useful screening approach to detect which of these minor variants are most impactful for viral fitness *in vitro*---i.e., those most frequently observed and/or rapidly selected in newly cultured clinical isolates. Intriguingly, both the UL13 and UL14 variants observed here were also detected in the initial culture passages of the genital HSV-1 isolate v29 ([@veaa013-B59]).

These data lay the foundation for a number of subsequent explorations using similar approaches. First, as mentioned above, it is a goal of our lab and others to model the dynamics of HSV-1 infection that occur in human patients in a controlled setting of laboratory culture. Ideally, this controlled setting would minimize the genetic drift observed here in Vero cell culture. To minimize HSV-1 genetic drift, it may be useful to explore using alternative cell lines (e.g., species-matched or with intact interferon signaling, both of which are missing in Vero cells) or by using a different multiplicity of infection, or by changing the duration of infection. The *in vitro* evolution approach could also be used to investigate HSV-1's response to specific selective pressures, such as exposure to antibodies, complement, or antiviral drugs. This type of *in vitro* evolution experiment has been performed with other viruses ([@veaa013-B17]; [@veaa013-B26]; [@veaa013-B40]; [@veaa013-B11]), though more frequently with RNA viruses rather than DNA viruses. While conventional reverse genetic approaches allow for detailed examination of the function of a specific gene product, forward genetic approaches such as *in vitro* evolution passaging experiments will allow us to study how the entirety of the viral genome responds to selective pressures. In addition, the unbiased approach of forward genetics enables the exploration of individual missense variants, as well as epistatic interactions of variants, and even copy number variants, as seen as prior studies ([@veaa013-B17]; [@veaa013-B26]; [@veaa013-B40]; [@veaa013-B11]). These experiments may be especially fruitful in the case of large DNA viruses like HSV-1, where multiple genes have pleiotropic and/or unknown functions, or undefined networks of interactions.
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